Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.56
-0.1600-9.30%
Post-market: 1.560.00000.00%18:16 EDT
Volume:3.11M
Turnover:4.96M
Market Cap:129.44M
PE:-0.54
High:1.69
Open:1.66
Low:1.52
Close:1.72
Loading ...

Editas Medicine Inc: Intends to Share Pre-Clinical Data and Further Development Timelines From These Programs in Q1 of 2025

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Announces Strategic Transition to in Vivo Gene Editing Company With Intent to Achieve Human Proof of Concept in Approximately Two Years

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

GlobeNewswire
·
13 Dec 2024

Wells Fargo Downgrades Editas Medicine to Equal Weight From Overweight, Cuts Price Target to $4 From $7

MT Newswires Live
·
11 Dec 2024

Editas Medicine downgraded to Equal Weight from Overweight at Wells Fargo

TIPRANKS
·
11 Dec 2024

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

Zacks
·
11 Dec 2024

Editas Medicine Updates RUBY Trial with Promising Results

TIPRANKS
·
10 Dec 2024

Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'

MT Newswires Live
·
10 Dec 2024

Editas Medicine reports updated clinical data from RUBY trial of Reni-cel

TIPRANKS
·
10 Dec 2024

Editas Medicine Reports Updated Clinical Data From the Ruby Trial of Reni-Cel in Patients With Severe Sickle Cell Disease at the American Society of Hematology (Ash) Annual Meeting

THOMSON REUTERS
·
10 Dec 2024

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswire
·
10 Dec 2024

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Zacks
·
05 Dec 2024

Editas cut to underperform by BofA, price objective slashed to $1

seekingalpha
·
26 Nov 2024

Bank of America Securities downgrades Editas Medicine (EDIT) to a Sell

TIPRANKS
·
25 Nov 2024

BofA Securities Downgrades Editas Medicine to Underperform

MT Newswires Live
·
25 Nov 2024

Editas Medicine downgraded to Underperform from Buy at BofA

TIPRANKS
·
25 Nov 2024